3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
69
Triple Negative Breast Neoplasms
32
Ovarian Neoplasms
21
Neoplasm Metastasis
10
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Fanconi Anemia, Complementation Group D1
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Recurrence
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Inflammatory Breast Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian
1
Interventions
pembrolizumab
3
Trastuzumab
3
Sunitinib
3
Magnetic Resonance Spectroscopy
3
selpercatinib
2
palbociclib
2
lenvatinib
2
larotrectinib
2
belinostat
2
Surveys and Questionnaires
2
Specimen Handling
2
Sirolimus
2
Nivolumab
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
Disulfides
2
Biopsy
2
vandetanib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
tipifarnib
1
temsirolimus
1
spartalizumab
1
sapanisertib
1
romidepsin
1
relatlimab
1
regorafenib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
olaparib
×
Breast
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled